Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Rescinding A Refuse-To-File: A Precedent Of Sorts

Apr 18 2018

• By Michael McCaughan

Related Content

Alkermes Refuse-To-File Reversal: Is It Really Good News For Anyone?

Apr 18 2018

Refusal Reversal: Alkermes Review Back On Track, But Could Still Be Bumpy

Apr 17 2018

Amneal Loses Bid For 180-Day Generic Exclusivity On Namenda XR

Jan 30 2018

Generic Exclusivity Suit Says US FDA Can’t Deny Prize If It Asks For Extra Data

Feb 01 2017

Related Companies

Alkermes plc

Amneal Pharmaceuticals, Inc.

Additional Topics

United States Drug Review Drug Approval Standards FDA Regulation Neurology BioPharmaceutical

More from Product Reviews

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window